Serum levels of macrophage migration inhibitory factor are associated with rheumatoid arthritis course

Rheumatology International

Volumn 32, Issue 8, 2012, Pages 2307-2311

  Llamas Covarrubias, Mara Anaís ^a   Valle, Yeminia ^a   Navarro Hernández, Rosa Elena ^a   Guzmán Guzmán, Iris Paola ^a   Ramírez Dueñas, María Guadalupe ^a   Rangel Villalobos, Héctor ^a   Estrada Chávez, Ciro ^b   Muñoz Valle, José Francisco ^a  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b INSTITUTO DERMATOLÓGICO DE JALISCO DR JOSÉ BARBA RUBIO   (Mexico)

Author keywords

Clinical activity; Disease evolution; MIF; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; CHLOROQUINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HYDROXYCHLOROQUINE; LEFLUNOMIDE; MACROPHAGE MIGRATION INHIBITION FACTOR; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE DURATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STATISTICAL ANALYSIS;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MEXICO; MIDDLE AGED; PROGNOSIS; RHEUMATOID FACTOR; SEVERITY OF ILLNESS INDEX; UP-REGULATION; YOUNG ADULT;

EID: 84866236870     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-011-1951-6     Document Type: Article

References (19)

1. McInnes IB, Schett G (2007) Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7:429-442
2. David JR (1966) Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA 56:72-77
3. Calandra T, Roger T (2003) Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3:791-800
4. Denkinger CM, Metz C, Fingerle-Rowson G et al (2004) Macrophage migration inhibitory factor and its role in autoimmune diseases. Arch Immunol Ther Exp 52:389-400
5. Willeke P, Gaubitz M, Schotte H et al (2007) Increased serum levels of macrophage migration inhibitory factor in patients with primary Sjögren's syndrome. Arthritis Res Ther 9:R43
6. Santos LL, Morand EF (2009) Macrophage migration inhibitory factor: a key cytokine in RA, SLE and atherosclerosis. Clin Chim Acta 399:1-7. doi:10.1016/j.cca.2008.09.014
7. Leech M, Metz C, Hall P et al (1999) Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflamatory function and regulation by glucocorticoids. Arthritis Rheum 42:1601-1608
8. Prevoo MLL, Van't Hof MA, Kuper HH et al (1995) Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44-48
9. Weinblatt ME, Kremer JM, Bankhurst AD et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving meth-otrexate. N Engl J Med 340:253-259
10. Thaler K, Chandiramani DV, Hansen RA et al (2009) Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project. Biologics 3:485-498
11. Nishimoto N, Miyasaka N, Yamamoto K et al (2009) Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 68:1580-1584
12. Leech M, Metz C, Santos L, Peng et al (1998) Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis. Arthritis Rheum 41:910-917
13. Onodera S, Ohshima S, Tohyama H et al (2007) A novel DNA vaccine targeting macrophage migration inhibitory factor protects joints from inflammation and destruction in murine models of arthritis. Arthritis Rheum 56:521-530
14. Leech M, Metz C, Bucala R et al (2000) Regulation of macrophage migration inhibitory factor by endogenous glucocorticoids in rat adjuvant-induced arthritis. Arthritis Rheum 43:827-833
15. Martinez A, Orozco G, Varadé J et al (2007) Macrophage migration inhibitory factor gene: influence on rheumatoid arthritis susceptibility. Hum Immunol 68:744-747
16. Radstake TR, Sweep FC, Welsing P et al (2005) Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum 52:3020-3029
17. Wheelhouse NM, Dowidar N, Dejong CHC et al (2006) The effects of macrophage migratory inhibitory factor on acute-phase protein production in primary human hepatocytes. Int J Mol Med 18:957-961
18. Morand EF, Leech M, Weedon H et al (2002) Macrophage migration inhibitory factor in rheumatoid arthritis: clinical correlations. Rheumatology (Oxford) 41:558-562
19. Bacher M, Metz CN, Calandra T, Mayer et al (1996) An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 93:7849-7854